Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
DALLAS, Sept. 13, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the Phase 2 STARLIGHT trial are expected in H1 2023.
- "We are excited by the therapeutic potential of MCO-010, supported by robust data from previous preclinical and clinical studies," said Sulagna Bhattacharya, CEO of Nanoscope.
- The Phase 2 STARLIGHT open-label trial ( NCT05417126 ) enrolled six subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.
- & Nancy J. Greene Chair and Professor of Ophthalmology at the University of Miami and principal investigator in the Phase 2 STARLIGHT trial.
- The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients ( NCT05417126 ).